Status and phase
Conditions
Treatments
About
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
Full description
This is an open label, multiple ascending dose (MAD) study, in which the safety of THN391 will be assessed in escalating doses. This study will enroll a total of approximately 21 participants into 3 sequential dose-escalating cohorts. Participants will receive 3 monthly THN391administrations.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
21 participants in 1 patient group
Loading...
Central trial contact
Liza Wallace; Joel Naor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal